Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
Date:2/3/2009

al work for urocortin 2 was successfully completed, and we advanced another compound, a VMAT2 inhibitor, now ready for clinical development. We pushed all these initiatives forward while meeting our main financial goal to end 2008 with over $100 million in cash and investments," said Kevin C. Gorman, President and CEO of Neurocrine Biosciences.

2009 Financial Guidance

Exclusive of any new partnering agreements, the Company expects to have a cash burn in 2009 of approximately $50 to $55 million. This projected burn includes all the activities necessary for completion of the Phase II program for elagolix and requesting the end of Phase II meeting with the FDA in the fourth quarter of 2009.

Pipeline Highlights

The Company's clinical development group and corporate partners are advancing its lead programs through development. Neurocrine scientists continue to build the Company's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

GnRH Antagonists in Expanded Phase II Clinical Trials for Endometriosis

Elagolix for Endometriosis

During 2008, the Company announced the positive safety and efficacy results from the completed 6-month treatment phase of its Phase IIb clinical trial (PETAL Study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix.

The primary endpoint, percent change from baseline in mean bone mineral density (BMD) demonstrated elagolix did not induce significant bone loss over the six month treatment period. Additionally, elagolix also met the secondary endpoints of improvement in endometriosis symptoms using several different scales for endometriosis pain. The 6-month results from this study, together with data from the other Phase II studies, will be the basis for secur
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2014)... LIVERMORE, Calif. The Department of Defense,s Defense ... National Laboratory (LLNL) up to $2.5 million to ... to record and stimulate neurons within the brain ... week. , The research builds on the understanding ... in certain regions of the brain encode information, ...
(Date:7/8/2014)... times higher when auditors were visible to healthcare workers ... a study in a major Canadian acute care hospital. ... effect in hand hygiene compliance monitoring using an electronic ... in the BMJ Quality & Safety Journal , ... study as part of her Master,s thesis while a ...
(Date:7/8/2014)... have discovered a biomarker that could give expecting mothers ... reliably predict that a pregnant woman may develop preeclampsia, ... pregnancy. , Preeclampsia is a cardiovascular disorder generally occurring ... delivery, creating immediate and potentially lifelong risks to both ... protein in the urine, and is typically diagnosed in ...
(Date:7/8/2014)... Johnson Foundation/Harvard School of Public Health (HSPH) poll released ... lives finds that about half of the public (49%) ... experience in the past year. Nearly half (43%) reported ... More than half of those who experienced a great ... many overall responsibilities and financial problems were contributors (54% ...
(Date:7/8/2014)... Military physicians will soon pick up joysticks instead of textbooks ... serious health threats. , James Gerard, M.D., a professor of ... from the Department of Defense Office of Naval Research ... video game that will train physicians on pediatric emergency room ... one of the most popular tools gaming to ...
Breaking Medicine News(10 mins):Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3Health News:Poll finds health most common major stressful event in Americans' lives last year 2Health News:Poll finds health most common major stressful event in Americans' lives last year 3Health News:Poll finds health most common major stressful event in Americans' lives last year 4Health News:Save, don't kill: SLU pediatrician to develop educational video game for training military physician 2
... multiple sclerosis (MS), the myelin that surrounds the axons of ... resulting in slowed and disrupted nerve impulses and, ultimately, axon ... major component of the myelin sheath and when used as ... which is used as an animal model of human MS. ...
... of Nepalese doctors has developed a drug that is ... media reported Friday . ,The drug also ... Health Organization (WHO), reported The Himalayan Times daily.Doctors at ... 390 typhoid patients. ,,The team compared the ...
... standard explanation of why AIDS/HIV infection in Australia is back ... the virus is not the death sentence it once ... unprotected sex. ,A recent court case in Melbourne ... men and trying to infect 14 others suggests that something ...
... boat on the Yamuna River that flows past India's capital, it's ... water's surface by rotting sewage -- and that's after at ... ,Now, with New Delhi to host the Commonwealth Games ... being built on the stinking river's banks, India must do in ...
... measures to ensure substandard drugs are stopped from reaching ... a raft of safety scandals, state press reported ... will have to abide by new regulations to improve ... corruption within the industry, the China Daily reported. ...
... Dr. Eric A. Cohen, a researcher at the IRCM (Institut ... on Friday, July 13, in PLoS Pathogens a discovery that ... of drugs to combat HIV. ,Human immunodeficiency virus ... called CD4+T lymphocytes in infected individuals, resulting in a compromised ...
Cached Medicine News:Health News:Autoimmune Response in Multiple Sclerosis 2Health News:Millions Spent, but the Indian Capital's River Still Stinks 2Health News:Millions Spent, but the Indian Capital's River Still Stinks 3
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... revised Concepts in Clinical Pharmacokinetics , a web-based ... Georgia. Developed in cooperation with the American Society of ... Continuing Education and College of Pharmacy, the new Online ... fundamental principles of absorption, distribution, metabolism, and the elimination ...
... preeminent law office of Nurenberg, Paris, Heller & ... Johnson & Johnson,s artificial joint replacement company DePuy ... damages resulting from the company,s now-recalled hip replacement ... District of Ohio, Eastern Division) ...
Cached Medicine Technology:Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia 2Newly Revised Concepts in Clinical Pharmacokinetics Web-Based Continuing Education Course Offered by the University of Georgia 3DePuy Orthopaedics Accused of Deceiving Hip Replacement Patients 2DePuy Orthopaedics Accused of Deceiving Hip Replacement Patients 3
This legless table has adjustable height and round post. Pad sold separately....
This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....
This table has adjustable height, round post, and universal clamp. Replacement 1" (5 cm) or 2" (2.5 cm) pad sold separately....
... An excellent choice for orthopedic procedures. ... width to 24" for the ... clamps quickly attach to any O.R. ... easy C-Arm access and stability. ...
Medicine Products: